The LIBRETTO-431 phase III trial evaluated selpercatinib as a first-line treatment for advanced RET fusion-positive NSCLC in comparison to platinum-based chemotherapy with or without pembrolizumab [82]. This evidence concerns the gene RET and non-small cell lung carcinoma.